每经AI快讯，戴维医疗1月5日晚间发布公告称，公司全资子公司宁波维尔凯迪医疗器械有限公司于近 日收到浙江省药品监督管理局颁发的1项《医疗器械注册证》。产品名称为"电子内窥镜图像处理器"。 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经头条（nbdtoutiao）——秒光！1499元飞天茅台上线即空，i茅台App冲上苹果购物榜第一，10万用 户已下单！经销商同价做回馈，1000箱很快卖完 每日经济新闻 （记者 曾健辉） ...

每经头条（nbdtoutiao）——秒光！1499元飞天茅台上线即空，i茅台App冲上苹果购物榜第一，10万用 户已下单！经销商同价做回馈，1000箱很快卖完 （记者 曾健辉） 每经AI快讯，九强生物1月5日晚间发布公告称，北京九强生物技术股份有限公司于近日收到北京市药 品监督管理局颁发的《医疗器械注册证》。包括"铁测定试剂盒（亚铁嗪法）"等产品。 ...

Core Viewpoint - The company has signed a strategic cooperation agreement with Inspur Digital Technology (Shanghai) Co., Ltd. to promote innovation and industrialization in medical intelligence and information technology [1] Group 1: Cooperation Details - The cooperation aims to advance intelligent manufacturing of medical devices and consumables, as well as the research and production of medical robots [1] - Key areas of collaboration include medical intelligence and information, smart medical devices, medical robots, market synergy, and brand co-construction [1] Group 2: Agreement Impact - The agreement is effective upon the affixing of official seals by both parties and is expected to guide long-term cooperation [1] - It is anticipated that the agreement will not have a direct impact on the company's performance for the fiscal year 2026 and beyond [1]

智通财经APP讯，九强生物(300406.SZ)公告，公司近日收到北京市药品监督管理局颁发的《医疗器械注 册证》，包括：铁测定试剂盒(亚铁嗪法)、轻链λ测定试剂盒(免疫比浊法)、可溶性生长刺激表达基因2 蛋白测定试剂盒(磁微粒化学发光免疫分析法)。 ...

Group 1 - The company Huatai Medical announced on January 5 that it has repurchased approximately 400,000 shares through the Shanghai Stock Exchange, representing 0.29% of its total share capital of approximately 141 million shares [1] - The highest purchase price for the repurchased shares was 256 yuan per share, while the lowest was 235 yuan per share [1] - The total amount paid for the repurchased shares was approximately 99.923 million yuan [1] Group 2 - The iMaotai App saw a surge in popularity, reaching the top of the Apple shopping chart, with 10,000 users placing orders for the product [1] - The limited stock of 1,499 yuan Flying Moutai was sold out quickly, with 1,000 boxes being sold in a short period [1]

戴维医疗1月5日公告，公司全资子公司宁波维尔凯迪医疗器械有限公司电子内窥镜图像处理器获得浙江 省药品监督管理局颁发的医疗器械注册证。产品与本公司生产的电子内窥镜配套使用，用于在内窥镜诊 断和/或治疗手术中与电子内窥镜连接，有效地在监视器上显示内窥镜观察人体体腔的视场区域的图 像。以上产品医疗器械注册证的取得，有利于丰富公司产品线，进一步提高公司的核心竞争力，对公司 未来的经营成果将产生积极影响。目前尚无法预测该等产品对公司未来营业收入的影响。 ...

Market Overview - On January 5, 2026, the A-share market experienced a strong opening, with all three major indices rising collectively. The Shanghai Composite Index regained the 4000-point mark, closing up by 1.38% [1] - The Shenzhen Component Index increased by 2.24%, while the ChiNext Index rose by 2.85% [1] - The total trading volume in the Shanghai and Shenzhen markets exceeded 2.5 trillion yuan, marking a significant increase of over 500 billion yuan compared to the previous trading day [1] Sector Performance - The market saw a broad-based rally across various sectors, with notable gains in insurance, medical devices, medical services, shipbuilding, semiconductors, precious metals, gaming, electronic chemicals, and biopharmaceuticals [1] - The stocks in the brain-computer interface sector experienced a collective surge, with multiple companies such as Botao Bio, Daoshi Technology, Sanbo Brain Science, and others hitting the 20% daily limit up [1]

Group 1 - The brain-computer interface (BCI) sector in A-shares experienced a strong surge on January 5, 2026, with stocks like Botao Bio, Sino Medical, and Xiangyu Medical hitting the 20% daily limit up [1] - The medical device ETF rose by 5.6%, while the Hong Kong medical sector also saw gains, with the Hang Seng Pharmaceutical ETF and Hong Kong Stock Connect Medical ETF increasing by 6% and 5.7%, respectively [1] - Elon Musk's Neuralink announced plans for large-scale production of BCI devices in 2026, marking a significant shift from clinical validation to commercial-scale production [1][3] Group 2 - In 2025, China approved 76 innovative drugs for market, surpassing the 48 approved in 2024, with total transaction amounts for innovative drug licensing exceeding $130 billion and over 150 transactions, both setting historical records [1] - The medical device ETF (562600) tracks the CSI Medical Device Index, with the medical device industry comprising 89% and BCI content at 23.14% [3] - The Hang Seng Pharmaceutical ETF (159892) has a scale of 5.564 billion yuan, with top-weighted stocks including BeiGene [3]

宜安科技（300328.SZ）1月5日在投资者互动平台表示，您好！感谢您对公司的关注。公司第一款可降 解镁骨内固定螺钉的补正材料，目前尚有部分问题点正在进一步与评审老师沟通确认，待所有问题点明 确解决后，公司将立即启动补正材料的正式提交程序，谢谢！ 每经AI快讯，有投资者在投资者互动平台提问：请问公司的镁骨钉注册补正工作推进到哪一步了？公 司预计多久能完成注册审批？ （记者 曾健辉） ...

2026 年 1 月 5 日 公司研究 专注女性健康和美，"医疗+消费"双轮驱动 ——麦澜德（688273.SH）投资价值分析报告 要点 深耕盆底康复十余载，拓展女性全生命周期健康和美。公司成立于 2013 年，是 国内女性盆底功能障碍（PFD）市场的领导品牌。公司聚焦盆底及妇产康复器械 的研产销，拓展生殖抗衰、运动康复、轻医美、脑机接口等领域，通过自研和并 购，快速构建女性全生命周期产品矩阵。公司拥有聚焦超声、激光、电生理、电 刺激、磁刺激、高频等多种能量源技术，持续引领行业发展。截至 2025H1 末， 公司覆盖超 8700 家医院、6000 家院外专业机构，核心高管持股超 60%。 2018-2024 年公司营收/归母净利润 CAGR 为 19.8%/10.4%。 产品领先+渠道高效，盆底康复基本盘稳固。我国女性 PFD 患病率高，但就诊率 和治疗率低，潜在患者超 2.8 亿人，市场需求广阔。物理治疗为主流疗法，盆底 康复器械技术日益成熟。公司作为该领域龙头，已构建"筛查-评估-治疗-居家康 复"全闭环服务，并前瞻布局脑机接口等技术，其自主研发的 AI 辅助盆底生殖 康复诊治系统达"国际领先水平"，推动 ...